C3c antibodies are immunological tools targeting the C3c fragment of complement component 3 (C3), a central protein in the complement system. The complement system, a key part of innate immunity, enhances pathogen clearance, inflammation, and tissue homeostasis. C3 is cleaved during complement activation into C3a (anaphylatoxin) and C3b (opsonin). Further degradation of C3b generates C3c and C3dg. C3c, a stable degradation product, retains antigenic epitopes useful for detecting complement activation.
C3c antibodies are widely used in research and diagnostics to identify complement activation in diseases. In clinical settings, they help detect C3c deposits in tissues (e.g., renal biopsies in glomerulonephritis) or measure circulating C3c levels as a biomarker for systemic complement activation in autoimmune disorders, infections, or inflammatory conditions. Their specificity for C3c ensures differentiation from intact C3 or other cleavage fragments, providing insights into disease mechanisms and therapeutic monitoring.
These antibodies are essential in immunoassays (e.g., ELISA, immunohistochemistry) and flow cytometry, aiding both basic research and diagnostic workflows. Their role in identifying complement-driven pathology underscores their importance in understanding immune dysregulation and guiding targeted therapies.